Insmed Incorporated (Nasdaq:INSM), a US-based global biopharmaceutical company, announced on Friday that it has completed enrolment of adult patient in its pivotal ASPEN study of brensocatib.
ASPEN is a global, randomised, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients ages 12 to 85 years with non-cystic fibrosis bronchiectasis. More than 1,700 adult patients have been enrolled and randomised (1:1:1) to receive brensocatib 10mg, brensocatib 25mg, or placebo once daily for 52 weeks, followed by 4 weeks off treatment. The primary endpoint is the rate of pulmonary exacerbations over the 52-week treatment period.
Insmed anticipates reporting topline data from adults in the ASPEN trial in the second quarter of 2024.
Inogen acquires Physio-Assist, expanding respiratory product portfolio and global presence
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines